NCT05518578Phase 2Recruiting

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12-31Estimated
Enrollment · participants60Estimated
Source updated2026-04-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 25 participants

Before: 35 participants (planned). After: 60 participants (planned).

Primary completion date changed

Before: Oct 2024. After: 31 Dec 2027.

Check registry source